Journals / Ağrı / 2015 / Cilt: 27 - Sayı: 1

Opioid kullanımının değerini maksimize etmek: Hızlı salımlı oksikodon ağrı tedavisinde iyi bir seçenek midir?Gianpetrio

Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management?

Journal
Ağrı
Pages
1–11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tis article considers the option of an immediate release (IR) oral formulation for the management of pain.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Te modern approach to the management of pain involves optimizing all aspects of the process.
📊
Key Findings & Data:Against this background of measured approach to the use of analgesics, an immediate release (IR) oral formulation of the established opioid oxycodone has been developed to provide rapid onset of action and rate of titration, both of which could maximize temporal matching of dose with pain level and reduce total exposure to drug.
💡
Conclusion & Impact:Tis article considers the option of an immediate release (IR) oral formulation for the management of pain.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Te modern approach to the management of pain involves optimizing all aspects of the process. Tis includes utilization of pharmacologic and non-pharmacologic modalities, consideration of patient characteristics, proper matching of the physiol- ogy of the pain with the analgesic’s mechanism of action (pharmacodynamics, PD), and the onset and duration of action (pharmacokinetics, PK). No single agent or formulation satisfes all of the requirements for all patients. Aspirin and other non-steroidal anti-infammatory drugs (NDAIDs) are efective options for infammatory pain and, as is acetaminophen, for mild pain. Specialized agents are helpful for particular pains, such as for migraine headache. Opioids remain the standard op- tion for severe pain. Although they are generally a safe and efective option, opioids can produce dose-limiting adverse efects and have abuse potential. Te goal of pain therapy is thus to achieve the maximum pain relief with the least amount of opioid exposure. Against this background of measured approach to the use of analgesics, an immediate release (IR) oral formulation of the established opioid oxycodone has been developed to provide rapid onset of action and rate of titration, both of which could maximize temporal matching of dose with pain level and reduce total exposure to drug. Tis article considers the option of an immediate release (IR) oral formulation for the management of pain.

Özet

Ağrı tedavisine modern yaklaşım sürecin her yönüyle optimal düzeye getirilmesinden geçer. Bu yaklaşım farmakolojik olan ve ol- mayan yöntemlerin kullanılmasını, hastanın karakteristik özelliklerinin göz önüne alınmasını, ağrı fzyolojisinin analjeziğin etki mekanizması (farmakodinamisi), etkisinin başlama anı ve süresi (farmakokinetiği) ile uygun biçimde eşleştirilmesini içerir. Her- hangi bir tek ajan veya formülasyon hastaların tümünün her gereksinmesini karşılayamaz. Aspirin ve diğer steroit yapısında ol- mayan antienfamatuvar ilaçlar (NSAİİ’ler) infamatuvar ağrı, asetaminofen haff ağrıda etkilidir. Özel ilaçlar migren baş ağrısı gibi spesifk ağrılarda etkilidir. Opioidler şiddetli ağrıda standart seçenek olmayı sürdürmektedir. Genellikle güvenli ve etkili seçenek olmalarına rağmen opioidler dozla sınırlı advers etkilere neden olabildikleri gibi, kötüye kullanım potansiyele de sahiptirler. O halde ağrı tedavisinin amacı en düşük opioid dozuyla ağrının maksimum düzeyde yok edilmesini sağlamaktır. Bu analjezik kullanımına ilişkin yaklaşım temelinde, dozun ağrı düzeyiyle zamansal eşleşmesini maksimize edebilen ve ilaca total maruziyet seviyesini düşüren bilinen opioid oksikodonun hızlı salımlı (IR) ve hemen titre edilen oral formülasyonu geliştirilmiştir. Bu makale ağrı tedavisinde hızlı salımlı oral formülasyon (IR) seçeneğini göz önüne almaktadır.

🔖

Cite This Article

PERGOLIZZI, J. V., KÖKNEL, G. T., ZMPONGA, G., ERDİNE, S., TAYLOR, R., AYAN, B., BRAFFA, R. (2015). Opioid kullanımının değerini maksimize etmek: Hızlı salımlı oksikodon ağrı tedavisinde iyi bir seçenek midir?Gianpetrio. Ağrı, Cilt: 27 - Sayı: 1, 1–11. https://ajindex.com/articles/157259

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. World Health Organization. WHO’s pain ladder for adults. 1988; http://www.who.int/cancer/palliative/painladder/ en/. Accessed 7 May, 2013
  2. Kalso E. Oxycodone. J Pain Symptom Manage 2005;29(5 Suppl):47-56
  3. Smith H. Introduction to Opioids. New York: Oxford Univer- sity Press; 2013
  4. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Muss- hof F. CYP2D6 genotype dependent oxycodone metabo- lism in postoperative patients. PLoS One 2013;8(3):60239
  5. Smith H, Bruckenthal P. Implications of opioid analge- sia for medically complicated patients. Drugs Aging 2010;27(5):417-33
  6. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Ex- pert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxyco- done). Pain Pract 2008;8(4):287-313
  7. Chan S, Edwards SR, Wyse BD, Smith MT. Sex diferences in the pharmacokinetics, oxidative metabolism and oral bio- availability of oxycodone in the Sprague-Dawley rat. Clin Exp Pharmacol Physiol 2008;35(3):295-302
  8. Han H, Kass PH, Wilsey BL, Li CS. Age, gender, and earlier opioid requirement associations with the rate of dose es- calation in long-term opioid therapy. J Opioid Manag 2013;9(2):129-38
  9. Zacny JP. Morphine responses in humans: a retrospec- tive analysis of sex diferences. Drug Alcohol Depend 2001;63(1):23-8
  10. Christo PJ, Grabow TS, Raja SN. Opioid efectiveness, addic- tion, and depression in chronic pain. Adv Psychosom Med 2004;25:123-37
  11. Chou R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn 2009;119(7-8):469-77
  12. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13(2):58-68
  13. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the manage- ment of hip and knee osteoarthritis, Part II: OARSI evidence- based, expert consensus guidelines. Osteoarthritis Carti- lage 2008;16(2):137-62
  14. Basurto Ona X, Rigau Comas D, Urrútia G. Opioids for acute pancreatitis pain. Cochrane Database Syst Rev 2013;7:CD009179.